We’re pleased to announce of a listing agreement with Medtronic New Zealand Limited (“Medtronic”) for the supply of needles and syringes products.
PHARMAC is seeking feedback on a proposal to amend the distribution arrangements and access criteria for the funding of dasatinib (Sprycel) tablets for chronic myeloid leukaemia (CML) from 1 May 2019.
Closes: 5 pm on Wednesday, 30 January 2019
Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, through an agreement with AbbVie Ltd.
Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment.
We’re pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) are managed within the Pharmaceutical Schedule.
10 December 2018 Via email: Dear REQUEST FOR INFORMATION Thank you for your request dated 9 November 2018 under the Official Information Act 1982 (OIA)...
There is a change to the 2018/19 Invitation to Tender that was issued on 1 November 2018. These amendments have been uploaded to the webpage and e-portal as relevant.
PHARMAC invites proposals for the supply of various vaccines and influenza vaccines in New Zealand.
All proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 4pm NZT Friday 18 January 2019 - RFx ID 20433854.
If you have any questions about this RFP, please post these on the Government Electronic Tenders Service (www.gets.govt.nz).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this RFP to be kept up to date.
We’re pleased to announce that colecalciferol oral liquid (vitamin D3, brand name Puria) will be funded in community and hospitals without restriction from 1 January 2019.
We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with BSN Medical Limited.
Decision to list Interventional Radiology products supplied by Edwards Lifesciences (New Zealand) Limited
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Edwards Lifesciences (New Zealand) Limited.
We’re pleased to announce a decision to list a new brand of iron polymaltose inj 50 mg per ml, 2 ml ampoule (Ferrosig) supplied by Sigma Healthcare.
PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners (NZ) Limited.
Closes: 5 pm on Friday, 18 January 2018
Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
PHARMAC is seeking your feedback on a multiproduct proposal with Merck Sharpe & Dohme (MSD). The proposal would list a new, once-daily presentation of raltegravir for the treatment of HIV, as well as make changes to the contractual arrangements for the currently funded presentation of raltegravir and for posaconazole.
Closes: 5pm Friday, 21 December 2018
Proposal involving treatments for multiple sclerosis, narcolepsy, and attention deficit and hyperactivity disorder
PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with Teva Pharma New Zealand Limited (Teva):
- fund a new pack size of modafinil (Modavigil) for narcolepsy in conjunction with a price decrease, from 1 February 2019
- fund a new brand of methylphenidate extended-release tablets (Methylphenidate ER - Teva) for attention deficit and hyperactivity disorder (ADHD) subject to the same restrictions as the Concerta and Ritalin LA brands of methylphenidate extended-release, following Medsafe approval
- fund a new 40 mg formulation of glatiramer acetate (Copaxone), which would mean fewer injections for people taking this medicine, from 1 February 2019
- delist the current 20 mg formulation of glatiramer acetate from 1 July 2019.
We are also proposing to change the distribution arrangements for three multiple sclerosis (MS) treatments: interferon beta-1-alpha (Avonex); Interferon beta-1-beta (Betaferon); and glatiramer acetate (Copaxone), to align with the other funded MS treatments.
Closes: 5 pm Friday, 21 December 2018
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016, and the 2017/18 Invitation to Tender, dated 2 November 2017.
PHARMAC has widened funded access to ceftriaxone to enable its use for the treatment of suspected meningococcal disease in the community. This change will be activated from 1 December 2018.
Decision to remove funding restrictions for alendronate 70 mg products, decrease price, and award sole supply
We’re pleased to announce that the funding restrictions on alendronate 70 mg products will be removed from 1 February 2019. At the same time, the price and subsidy of these products will decrease.
PHARMAC is seeking feedback on a proposal to list a range of Ostomy Products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019, through a listing agreement with Omnigon Pty Ltd.
Closes: 4pm Friday, 14 December 2018.
PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 March 2019, through a provisional agreement with Medtronic New Zealand Limited.
Closes: 4pm Friday, 14 December 2018.